Psoriatic arthritis: novel targets add to a therapeutic renaissance

No Thumbnail Available
File version
Author(s)
Nash, Peter
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2018
Size
File type(s)
Location
License
Abstract

Psoriasis is the most common chronic autoinflammatory skin disease, affecting 2–3% of the world's population, of whom 10–30% have psoriatic arthritis. As a result of better elucidation of crucial pathogenic inflammatory pathways and the advent of biologic disease-modifying anti-rheumatic therapies, the treatment of psoriatic arthritis has undergone a renaissance.

Journal Title

Lancet

Conference Title
Book Title
Edition
Volume

391

Issue

10136

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Biomedical and clinical sciences

Clinical sciences

Science & Technology

Life Sciences & Biomedicine

Medicine, General & Internal

General & Internal Medicine

RESIDENT T-CELLS

Persistent link to this record
Citation

Nash, P, Psoriatic arthritis: novel targets add to a therapeutic renaissance, Lancet, 2018, 391 (10136), pp. 2187-2189

Collections